Thermo Fishr Sci Stock Price, News & Analysis

Thermo Fisher Scientific (NYSE: TMO) has completed its acquisition of Solventum's Purification & Filtration business for $4.0 billion in cash. The acquired business, now renamed as Thermo Fisher's Filtration and Separation business, will be integrated into the Life Sciences Solutions segment.

The acquisition strengthens TMO's bioproduction portfolio with advanced filtration technologies and expands its reach into industries requiring ultra-pure water. The acquired business is expected to generate $750 million in revenue for 2025 and achieve mid- to high-single digit organic growth. The transaction is projected to be dilutive to adjusted EPS by $0.06 in the first year, with expected synergies of $125 million in adjusted operating income by year five.

Solventum (NYSE: SOLV) has completed the sale of its Purification & Filtration (P&F) business to Thermo Fisher Scientific (NYSE: TMO) for $4.0 billion in cash. The company will receive net proceeds of $3.4 billion, primarily allocated to debt reduction.

Following this strategic divestiture, Solventum has updated its FY2025 guidance, projecting organic sales growth of 2.0-3.0% and raising its adjusted EPS range to $5.88-$6.03. The company expects operating margins at the high end of 20-21% range and reduced net interest expense of $400 million, down from $450 million previously forecasted.

Thermo Fisher Scientific (NYSE:TMO), the world leader in serving science, has announced that its Chairman, President and CEO Marc N. Casper will participate in a fireside chat as part of the J.P. Morgan CEO Call Series. The event is scheduled for September 5th, 2025, at 1:00 p.m. ET. Investors and interested parties can access the live webcast through the Investors section of Thermo Fisher's website at www.thermofisher.com.

Thermo Fisher Scientific (NYSE: TMO) announced that CFO Stephen Williamson will retire effective March 31, 2026, after serving in the role since 2015. Jim Meyer, currently vice president of financial operations, will succeed Williamson as CFO effective March 1, 2026.

Under Williamson's tenure as CFO, TMO's market capitalization increased by nearly 300 percent. Meyer, age 46, joined Thermo Fisher in 2009 and has held various finance leadership positions. The company has planned a one-month transition period where both executives will work together to ensure continuity in leadership.

Thermo Fisher Scientific (NYSE:TMO) reported strong Q2 2025 financial results with revenue growing 3% to $10.85 billion and GAAP EPS increasing 6% to $4.28. The company's adjusted EPS was $5.36, while adjusted operating margin stood at 21.9%.

During the quarter, TMO launched several next-generation instruments including the Orbitrap Astral Zoom mass spectrometer and Krios 5 Cryo-TEM. The company also expanded its DynaDrive single-use bioreactor portfolio and announced a strategic partnership with Sanofi to acquire its Ridgefield, New Jersey sterile fill-finish site.

The company demonstrated effective cost management through its PPI Business System, enabling strong operational performance despite challenging market conditions.

Thermo Fisher Scientific (NYSE:TMO) has announced an expansion of its strategic partnership with Sanofi through the acquisition of Sanofi's sterile manufacturing facility in Ridgefield, New Jersey. The state-of-the-art sterile fill-finish and packaging facility employs over 200 workers who will join Thermo Fisher upon deal completion.

Under the agreement, Thermo Fisher will continue manufacturing Sanofi's portfolio of therapies while expanding the site's capacity to meet growing U.S. manufacturing demand from pharma and biotech customers. The facility will join TMO's existing sterile fill-finish network, which includes sites in Greenville, North Carolina and Plainville, Massachusetts. The transaction is expected to close in H2 2025, after which the facility will become part of Thermo Fisher's pharma services business.

Thermo Fisher Scientific (NYSE:TMO), a global leader in serving science, has announced a quarterly cash dividend. The company's Board of Directors has declared a dividend of $0.43 per common share. The dividend will be paid on October 15, 2025, to shareholders who are on record as of September 15, 2025.

Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, has scheduled its second quarter 2025 earnings conference call for Wednesday, July 23, 2025, at 8:30 a.m. ET. The company will release its financial results before the market opens on the same day.

Investors can access the call by dialing (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S., using access code 523661. A live webcast will be available on the "Investors" section of www.thermofisher.com. The earnings release and related materials will be posted under the "Financials" section. A replay will remain accessible through October 21, 2025.

Thermo Fisher Scientific (NYSE: TMO) has unveiled two groundbreaking mass spectrometers at ASMS 2025: the Orbitrap Astral Zoom and Orbitrap Excedion Pro. The Orbitrap Astral Zoom delivers 35% faster scan speeds, 40% higher throughput, and 50% expanded multiplexing capabilities, enhancing sensitivity and experimental flexibility for proteomics research. The Orbitrap Excedion Pro, designed for biopharma applications, is the first platform combining next-generation Orbitrap hybrid mass spectrometry with alternative fragmentation technologies, accelerating biological drug development particularly for monoclonal antibodies. These innovations aim to advance precision medicine and research in complex diseases like Alzheimer's and cancer, while strengthening Thermo Fisher's position in omics and proteomics research solutions.